Endoscopy Equipment Global Market Report 2022: Growing Focus of Hospitals to Invest in Technologically-Advanced Endoscopy Instruments and Expand Endoscopy Units Bolsters Sector

The “Endoscopy Equipment Market by Product (Endoscope (Flexible, Rigid, Capsule, Robot-assisted, Disposable), Visualization Systems (Video Converters, Recorders, Processors), Other endoscopic, Accessories), Application, End User – Global Forecast to 2027” report has been added to ResearchAndMarkets.com’s offering.

The global endoscopy equipment market is projected to reach USD 40.6 billion by 2027 from USD 28.9 billion in 2022, at a CAGR of 7.0%.

The competitive landscape includes the analysis of the key growth strategies adopted by major players between January 2019 and May 2022. Players in the global endoscopy equipment market have employed various strategies to expand their global footprint and increase their market shares such as agreements, divestitures, expansions, and acquisitions.

The wireless displays and monitors segment is expected to account for the largest share of the visualization systems market

The wireless displays and monitors segment accounted for the largest share of the visualization systems markets in the forecast period. The large share of this segment can be attributed to factor that several medical device manufacturers have commercialized 3D-compatible endoscopes. These devices have significantly enhanced surgical precision and gained attention as they provide extremely accurate three-dimensional images of the area being operated. Technological advancements in these devices are further expected to propel their demand in the coming years.

Gastrointestinal endoscopy segment is expected to account for the largest share of the endoscopy equipment market

Based on application, the gastrointestinal endoscopy segment accounted for the largest share of the endoscopy equipment market in the forecast period. This segment is also expected to witness the highest CAGR of 8.4% during the forecast period. The largest share and the highest growth rate of this segment can be attributed to the significant increase in the number of adults in the US undergoing CRC screening, which is a major market for endoscopy products, is expected to sustain the growth of the GI endoscopy segment. Colonoscopy is a widely used endoscopic procedure in the US, considered the gold standard for colorectal cancer screening; approximately 15 million colonoscopies are performed per year.

Hospitals segment holds the highest market share in the endoscopy equipment market

Based on end user, the hospitals segment is likely to dominate the endoscopy equipment market during the forecast period owing to the growing healthcare sector in emerging economies, the increasing out-of-pocket healthcare expenditure across the world, and the rising demand for endoscopic procedures are the other major factors supporting the growth of the hospital segment.

North America to dominate the endoscopy equipment market during the forecast period

The endoscopy equipment market in North America dominated the endoscopy equipment market in the forecast period. The largest share of North America in the global market is attributed to the favorable reimbursement policies for endoscopic procedures in the high healthcare spending in the country, favorable reimbursement policies for endoscopic procedures, an increased incidence of cancer, constant research on endoscopy techniques, and a high number of FDA approvals for endoscopy systems in the US.

Market Dynamics

Drivers

Surging Requirement for Endoscopy to Diagnose and Treat Target Diseases
Increasing Investments, Funds, and Grants by Governments and Other Organizations Worldwide
Growing Focus of Hospitals to Invest in Technologically-Advanced Endoscopy Instruments and Expand Endoscopy Units
Ongoing Advancements in Endoscopic Technologies to Ensure Patient Safety and Achieve More Accurate Treatments
Rising Requirement of Endoscopy Procedures due to Increased Incidence of Chronic Diseases
Increasing Preference for Minimally Invasive Surgeries
Adoption of Single-Use Endoscopy Instruments to Prevent Infectious Diseases and Offer Increased Safety
Rising Focus of Medical Specialists to Shift from Manual to Automated Endoscopy Reprocessing

Restraints

Unfavorable Healthcare Reforms in US
High Overhead Costs of Endoscopy Procedures with Limited Reimbursement in Developing Countries
High Risk of Viral Infections During Endoscopic Procedures

Opportunities

Booming Healthcare Sector in Developing Economies

Challenges

Product Recalls Witnessed by Major Market Players
Infections Caused by Some Endoscopy Products Offered by Giant Companies
Shortage of Trained Physicians and Endoscopists

Key Topics Covered:

1 Introduction

2 Research Methodology

3 Executive Summary

4 Premium Insights

5 Market Overview

6 Endoscopy Equipment Market, by Product
6.1 Introduction
6.2 Endoscopes
6.3 Visualization Systems
6.4 Other Endoscopy Equipment
6.5 Accessories
6.5.9 Other Accessories

7 Endoscopy Equipment Market, by Application
7.1 Introduction
7.2 Gastrointestinal Endoscopy
7.3 Laparoscopy
7.4 Obstetrics/Gynecology Endoscopy
7.5 Arthroscopy
7.6 Urology Endoscopy (Cystoscopy)
7.7 Bronchoscopy
7.8 Ent Endoscopy
7.9 Mediastinoscopy
7.9.1 Rising Cases of Lung Cancer, Lymphoma, Tuberculosis, and Lung Infections to Drive Market
7.10 Other Applications

8 Endoscopy Equipment Market, by End-User
8.1 Introduction
8.2 Hospitals
8.3 Ambulatory Surgery Centers/Clinics
8.4 Other End-Users

9 Endoscopy Equipment Market, by Region

10 Competitive Landscape

11 Company Profiles

12 Appendix

Companies Mentioned

Ambu A/S
Arthrex, Inc.
B. Braun Melsungen Ag
Boston Scientific Corporation
Capsovision, Inc.
Carl Zeiss Ag
Conmed Corporation
Cook Medical
Dantschke Medizintechnik GmbH & Co. Kg
Fortimedix Surgical B.V.
Fujifilm Holdings Corporation
Hoya Corporation
Intuitive Surgical, Inc.
Johnson & Johnson
Karl Storz Se & Co. Kg
Laborie Medical Technologies, Inc.
Medtronic, plc
Myelotec, Inc.
Nipro Corporation
Olympus Corporation
Richard Wolf GmbH
Smith & Nephew plc
Steris plc
Stryker Corporation
Teleflex Incorporated
The Cooper Companies, Inc.

For more information about this report visit here.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”